TIDMSTX

RNS Number : 3693P

Shield Therapeutics PLC

31 August 2017

Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017

London, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company's late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.

An audio webcast of the presentation will be available in the events section of the Company's website, or by clicking here. A replay will be available for a limited time following the presentation.

About Shield Therapeutics

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.

For further information please contact:

Shield Therapeutics plc +44 (0) 207 186 8500

Joanne Estell, Chief Financial Officer

Karl Keegan, Corporate Development Director

   Nominated Adviser and Joint Broker                                             +44 (0)20 3100 2222

Liberum Capital Limited

Christopher Britton

Steve Pearce

Jonathan Wilkes-Green

Joint Broker +44 (0)20 7418 8900

Peel Hunt LLP

James Steel

Alastair Rae

Oliver Jackson

Financial PR Adviser +44 (0)203 709 5700

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

shieldtherapeutics@consilium-comms.com

U.S Investor Relations + 1 (212)-599-1265

Lazar Partners Ltd.

Matthew Ventimiglia

mventimiglia@lazarpartners.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDMGFRMGFGNZZ

(END) Dow Jones Newswires

August 31, 2017 02:01 ET (06:01 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Shield Therapeutics Charts.
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Shield Therapeutics Charts.